ERBB2 and breast cancer: This retrospective cohort study included women diagnosed with early‐stage, HR+/HER2‐ breast cancer from 2011 to 2023 within the US‐based, electronic health record (EHR)‐derived, deidentified Flatiron Health Research Database.